<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03616509</url>
  </required_header>
  <id_info>
    <org_study_id>END-GH-2017</org_study_id>
    <secondary_id>2017-002164-41</secondary_id>
    <nct_id>NCT03616509</nct_id>
  </id_info>
  <brief_title>GH in Adults With PWS, Effect on Hypotonia Evaluated by Functional MRI, Relationship With Strength and Body Composition</brief_title>
  <official_title>Treatment With Growth Hormone in Adults With PWS, Effect on Muscular Tone Evaluated by Functional MRI, Relationship With Strength and Body Composition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corporacion Parc Tauli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parc de Salut Mar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Corporacion Parc Tauli</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prader-Willi syndrome (PWS) is a genetic disorder associated with growth hormone (GH)
      deficiency, central hypotonia and hyperphagia that leads to life-threatening obesity.
      Treatment with GH in adult patients is not well stablished in guidelines of Health National
      System (HNS). The investigators has experience in the study of brain connectivity in these
      patients in relation to satiety. To date, there is no evidence about the effect of GH on
      central hypotonia (brain areas related with muscle tone maintenance). So, the main objective
      is to examine these anatomical areas before and one year after GH treatment.

      Methodology: Structural and functional magnetic resonance imaging to 30 PWS patients before
      and after GH treatment and we will compare them to a control group.

      Expected results: PWS group will show abnormal functional and structural connectivity in
      circuitry of muscle tone maintenance that will improve after GH treatment. These favorable
      changes and the absence of secondary effects will help to justify the use of this treatment
      and its inclusion in practical clinical guidelines of HNS for the management of this syndrome
      in the adulthood.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 19, 2017</start_date>
  <completion_date type="Anticipated">May 2, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>First phase: 2m with placebo Second phase: 12 m with growth hormone</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Examine brain connectivity areas related with muscle tone maintenance</measure>
    <time_frame>24 months</time_frame>
    <description>Examine brain connectivity areas related with muscle tone maintenance making a functional MRI while the subject is making motor maneuvers, before anf after 12 months on GH treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of strength</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluation of strength before and after 12 months on GH treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of body composition</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluation of body composition by Dual energy x-ray absorptiometry (DEXA) before and after 12 months on GH treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Prader-Willi Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo and Growth Hormone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 months on placebo followed by 12 months on GH</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Growth hormone</intervention_name>
    <description>12 months on Growth hormone, initial dose 0,2 mg per day, then adjusted by insulin like growth factor (IGF-1) level</description>
    <arm_group_label>Placebo and Growth Hormone</arm_group_label>
    <other_name>Genotonorm Miniquick</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 months on placebo, sodium chloride 0,9% injections</description>
    <arm_group_label>Placebo and Growth Hormone</arm_group_label>
    <other_name>Physiological serum (sodium chloride 0,9%)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PWS &gt;=18 years with growth hormone deficit

          -  Signed informed consent by the patients or their legal guardian

        Exclusion Criteria:

          -  Severe obesity

          -  No controled diabetes mellitus

          -  No treated obstructive sleep apnea or severe obstructive sleep apnea

          -  Active cancer

          -  Active psychosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olga Gimenez-Palop, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Corporacio Sanitària Parc Taulí</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parc Taulí Hospital Universitari</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 27, 2018</study_first_submitted>
  <study_first_submitted_qc>August 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2018</study_first_posted>
  <last_update_submitted>August 3, 2018</last_update_submitted>
  <last_update_submitted_qc>August 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Corporacion Parc Tauli</investigator_affiliation>
    <investigator_full_name>Olga Gimenez-Palop</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Growth Hormone</keyword>
  <keyword>Functional Magnetic Resonance</keyword>
  <keyword>Strength</keyword>
  <keyword>Body composition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prader-Willi Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

